Skip to main content
Log in

Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction

Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Anti-Hu paraneoplastic syndromes are usually associated with an underlying neoplasia, although a few patients who are anti-Hu-positive never develop cancer after long-term follow-up. Tumour therapy remains the mainstay of therapeutic options, and early immune therapy in parallel is advisable. When no tumour is found, immunologically-based therapies are nowadays the only options. Recent studies have shown rituximab associated with the tumour therapy to be effective for some patients with anti-Hu paraneoplastic syndrome. We report a case of a patient with anti-Hu antibodies-associated sensory neuronopathy and gastric pseudo-obstruction without an underlying neoplasia four years after the first manifestation who has achieved sustained improvement for two years after treatment with rituximab. This case report supports the effectiveness of rituximab in these syndromes, even for cases where no underlying neoplasia is demonstrated. Further studies are warranted in order to confirm these preliminary data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Graus F, Keime-Guibert F, Reñe R et al (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124:1138–1148. doi:10.1093/brain/124.6.1138

    Article  PubMed  CAS  Google Scholar 

  2. Lladó A, Carpentier AF, Honnorat J et al (2006) Hu-antibody-positive patients with or without cancer have similar clinical profiles. J Neurol Neurosurg Psychiatry 77:996–997. doi:10.1136/jnnp.2005.085753

    Article  PubMed  Google Scholar 

  3. Szabo A, Dalmau J, Manley G et al (1991) HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell 67:325–333. doi:10.1016/0092-8674(91)90184-Z

    Article  PubMed  CAS  Google Scholar 

  4. Honnorat J, Cartalat-Carel S (2004) Advances in paraneoplastic neurological syndromes. Curr Opin Oncol 16:614–620. doi:10.1097/01.cco.0000142486.89472.eb

    Article  PubMed  Google Scholar 

  5. Esposito M, Penza P, Orefice G et al (2008) Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol 86:363–364. doi:10.1007/s11060-007-9479-z

    Article  PubMed  Google Scholar 

  6. Shams’ili S, Beukelaar J, Willem Gratama J et al (2006) An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253:16–20. doi:10.1007/s00415-005-0882-0

    Article  PubMed  Google Scholar 

  7. Byrne T, Mason WP, Posner JB, Dalmau J (1997) Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 62:276–278. doi:10.1136/jnnp.62.3.276

    Article  PubMed  CAS  Google Scholar 

  8. Lladó A, Mannucci P, Carpentier AF et al (2004) Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology 63:1947–1949

    PubMed  Google Scholar 

  9. Darnell JC, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554. doi:10.1056/NEJMra023009

    Article  PubMed  CAS  Google Scholar 

  10. Graus F, Illa I, Agusti M, Ribalta T et al (1991) Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci 106:82–87. doi:10.1016/0022-510X(91)90198-G

    Article  PubMed  CAS  Google Scholar 

  11. Gonzalez-Stawinski GV, Yu PB, Love SD et al (2001) Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody. Clin Immunol 98:175–179. doi:10.1006/clim.2000.4980

    Article  PubMed  CAS  Google Scholar 

  12. Arzoo K, Sadeghi S, Liebman HA (2002) Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 61:922–924. doi:10.1136/ard.61.10.922

    Article  PubMed  CAS  Google Scholar 

  13. Graus F, Dalmau J (2007) Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 20:732–737

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Dr Graus (Neurology Service, Hospital Clinic, Barcelona) for performing the antineuronal antibodies determination.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Isabel Bosca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coret, F., Bosca, I., Fratalia, L. et al. Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction. J Neurooncol 93, 421–423 (2009). https://doi.org/10.1007/s11060-008-9787-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9787-y

Keywords

Navigation